Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives $106.75 Average Target Price from Brokerages
Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the ...
Insider Monkey on MSN9d
Why Is Viking Therapeutics, Inc. (VKTX) Among the Best Multibagger Stocks to Buy Right Now?
We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look ...
Why Viking Therapeutics Stock Plummeted by 24% in December
Viking Therapeutics (NASDAQ: VKTX) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's ...
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street Analysts
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are ...
Marianna Mancini Sells 54,215 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) Stock
COO Marianna Mancini sold 54,215 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at ...
Hosted on MSN3d
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know
Viking Therapeutics, Inc. (VKTX) closed at $42.53 in the latest trading session, marking a -0.84% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.55% for the ...
Should You Buy the Dip on This High-Flying Stock?
It's been an excellent year for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech company. Thanks to impressive mid-stage ...
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...
Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating
J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...
SA Asks: Which biotechs are most likely to be acquired near-term?
Last year's first quarter saw a flurry of biotech takeover deals, starting off with Johnson & Johnson (JNJ)/Ambrx, Merck (MRK)/Harpoon, GSK (GSK)/Aiolos and Novartis(NVS)/Calypso in early January.
3 Stocks That Could Be Monster Winners in 2025
What do many kids like most about the coming of a new year? The fireworks. Investors don't mind seeing some fireworks in ...